版本:
中国

BRIEF-Medicines Co announces positive top-line results from day 90 interim analysis in ongoing Orion-1 Phase 2 study of PCSK9si

Oct 18 Medicines Co

* Medicines company announces positive top-line results from day 90 interim analysis in ongoing orion-1 phase 2 study of pcsk9si

* Medicines Co - PCSK9si was well tolerated and no material safety issue was observed in the day 90 interim analysis of unblinded safety data

* Medicines Co - expects data from day 180 follow-up in all 501 patients to be completed, analyzed and top-line results disclosed before end of 2016 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐